Search results: (10000)
News Pharmacological Profile of Mavacamten and Key Studies of Its Use in HCM Treatment
A new addition to the treatment options for hypertrophic cardiomyopathy, approved for use in European Union countries in June 2023, is the selective reversible cardiac myosin inhibitor mavacamten. The following review summarizes its fundamental pharmacological characteristics along with the results of several crucial clinical studies and highlights the potential integration of mavacamten into clinical practice.
News Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?
A recently published study by a team of authors from several American institutions focused on comparing the efficacy and safety of the 5th generation cephalosporin ceftaroline with the standard of care in the treatment of sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA).
News Hybrid Cooperating Complexes in Osteoarthritis Treatment
Intra-articular application of corticosteroids and hyaluronic acid is part of the treatment of osteoarthritis (OA) in patients for whom oral or topical treatment does not provide sufficient response. The following text addresses the lubricating and protective properties of synovial fluid and the associated choice of suitable intra-articular viscosupplementation, with an emphasis on innovative molecules with high concentrations of hyaluronic acid and low viscosity.
News What impact do the symptoms of primary biliary cholangitis have on the patient and their quality of life
Primary biliary cholangitis (PBC) is a serious chronic cholestatic autoimmune liver disease that predominantly affects middle-aged women and can lead to end-stage liver failure and the need for transplantation. Several studies published this year show a reduction in the quality of life of patients with this disease due to its accompanying symptoms.
News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer
The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.
News Detection of von Willebrand Disease
Von Willebrand disease (vWD) is an autosomal hereditary bleeding disorder. Its detection and diagnosis require several steps, including the initial suspicion of the presence of this disease.
News A Decade of Therapy Targeting B Lymphocytes in MS
Ocrelizumab is not only a pioneer but also a highly effective and still promising modality for the treatment of multiple sclerosis (MS) with excellent patient adherence and persistence.
News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.
News Identification of patients with advanced Parkinson's disease suitable for device-aided therapy (DAT)
To properly implement device-aided therapy in Parkinson's disease (PD) management, it is essential to timely identify patients in advanced stages of the disease who might benefit from this therapeutic approach. We summarize the useful tools that doctors can use to find these patients.
News Use of Bilastine in Pediatrics − Pathway to Improving Concentration and Performance of Young Allergy Sufferers
In the treatment of allergic diseases, especially in children, safety, good tolerability, simple dosing regimen, and non-sedative effects are the basic requirements for administered medications. Sedative side effects of treatment have a negative impact on sleep patterns and subsequently on children's performance in school. European professional societies recommend the use of modern second-generation antihistamines in the treatment of children. Studies confirm that bilastine, which meets these requirements, should be among the first-choice drugs.
News Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker
The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of prostate-specific antigen (PSA), free PSA (fPSA), and the isoform [-2]proPSA (p2PSA). Its use in prostate cancer diagnostics can reduce the number of unnecessary prostate biopsies compared to determining PSA alone. A recently published Czech study assessed the utility of PHI in evaluating the aggressiveness of prostate cancer. The study compared PHI values with the results of preoperative biopsy and postoperative prostate histology in men indicated for radical prostatectomy.
News Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension. Although it is an unpleasant complication, it does not – and should not – always be a reason to discontinue therapy. Fear of hypotension should not lead to not prescribing sacubitril/valsartan at all. We provide practical guidance on how to approach this clinical situation.
News Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study
The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago is now becoming a reality. From chemotherapy, through immunochemotherapy, to the use of molecules targeting apoptotic pathways of tumor cells, the prognosis for patients has markedly improved. However, the wide therapeutic spectrum also brings its own specifics and complications, and the correct sequencing of treatment lines and their selection for each individual is necessary, considering the nature of CLL, overall condition, and comorbidities.
News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.
News What is the significance of hormones in the pathophysiology of migraine?
Migraine is a complex neurovascular disease characterized by the dysfunction of the nociceptive trigeminovascular system in its pathophysiology. Its prevalence is 2-3 times higher in women than in men. The cause of this difference has not yet been fully elucidated, but it appears that the fluctuation of ovarian hormone levels and its influence on CGRP plays an important role. The following article summarizes findings on the hormonal influence of migraine and also discusses new prophylactic drugs – anti-CGRP antibodies.
News Principle of Slowed Wound Healing Due to Stress Revealed
There is no doubt that psychological stress significantly slows down the process of healing wounds. The principle of how this phenomenon occurs, however, has remained unexplained. Swiss scientists focused on macrophages. Their function is to remove pathogens from the healing wound.
News Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency
For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.
News Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
News New Recommendations for Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke – ESO Guidelines 2021
Intravenous thrombolysis is the only approved systemic reperfusion therapy for patients with acute ischemic stroke (AIS). The most commonly used thrombolytic is alteplase. Earlier this year, the European Stroke Organisation (ESO) issued new evidence-based recommendations for this clinical situation. They contain 40 points, summarized below are the most important ones.
News Genuair®/Pressair® Inhaler in the Treatment of COPD – Minimum Errors During Inhalation and High Patient Satisfaction
The article by German authors summarizes the results achieved with the Genuair® inhaler (marketed in the USA under the name Pressair®), highlighting its ease of use, simple patient training, low error rates during inhalation compared to other inhalers, and high patient satisfaction and willingness to continue treatment.
News Undiagnosed Hereditary Angioedema in Pregnancy – Case Study
Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
News Recommend Erdostein for children when treating with amoxicillin – symptoms of cough improve in almost 50% of cases within 3 days
Acute respiratory infections are usually treated empirically in primary care as the causative agent is not known. Amoxicillin is among the most commonly chosen antibiotics. Erdostein is a suitable addition to this antibiotic treatment for several reasons.
News Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain
Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free survival (PFS). At this year's virtual World Congress on Gastrointestinal Cancer of the European Society for Clinical Oncology (ESMO), held from June 30, a Spanish study on the efficacy of trifluridine/tipiracil in real-world clinical practice was presented.